Skip to content
1 min left
0% read
Twenty Twenty Therapeutics logo

Twenty Twenty Therapeutics

Technology Company
South San Francisco, California, USA
Founded 2020
58

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Share:

Twenty Twenty Therapeutics

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics, and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Our vision is to eliminate preventable blindness. By transforming the delivery of today's eye care, we are improving patient access to intuitive and affordable diagnostics and treatments. We believe it should be easy for doctors to deliver superior outcomes to their patients.

Our technology empowers patients to care for their own vision in between doctors' visits. To accomplish these goals, we develop, market, and commercialize transformative innovations in diagnostics, sensing, and preventative, medical, and surgical treatments for eye diseases.

We were formed in August 2020 as a joint venture between Verily Life Sciences, an Alphabet company, and Santen, a leading Japanese pharmaceutical company. We are passionate and committed to building and sustaining an inclusive and equitable working environment. Every member of our team enriches our diversity by exposing us to a broad range of views that help us understand and engage with the world, identify challenges, and discover, design, and deliver solutions.

The Twenty Twenty work environment empowers our team to do their absolute best work.

Frequently Asked Questions About Twenty Twenty Therapeutics

Twenty Twenty Therapeutics is a software company. Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market. Our vision is to eliminate preventable blindness.

By transforming the del.

Twenty Twenty Therapeutics has been operating since 2020. You can verify their legitimacy through their official website and social media presence.

Twenty Twenty Therapeutics operates in the software sector of the cryptocurrency industry. Compare Twenty Twenty Therapeutics with other software companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Twenty Twenty Therapeutics, research their track record (operating since 2020), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Twenty Twenty Therapeutics is based in South San Francisco, California, USA, has been operating since 2020. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Twenty Twenty Therapeutics is based in South San Francisco, California, USA, North America, with offices in South San Francisco, California, USA.

Twenty Twenty Therapeutics was founded in 2020. The company currently has 58 employees.

Twenty Twenty Therapeutics Details

Twenty Twenty Therapeutics Offices (3)

Twenty Twenty Therapeutics Tags

More About Twenty Twenty Therapeutics

Work Model Details
Employees work from physical offices.

Latest from Academy

XDC Investment Thesis Depends on Understanding One Key Trend

XDC Investment Thesis Depends on Understanding One Key Trend

By the end of 2025, the XDC Network had over $717 million in tokenized real-world assets. VERT Capital has invested about $375 million in tokenized bonds from Mottu and Banco Pine on the XDC Network and intends to increase this to $1B by 2026. The VERT Capital USDC private credit pools are about 48% of XDC's total RWA value, which is really important.

9m
Six Reasons Monad Price Prediction Models Keep Failing

Six Reasons Monad Price Prediction Models Keep Failing

Before Monad's network went live on November 24, 2025, guessing its price was pretty normal. Sources say Monad just got $225 million in Series A funding, which puts their value at around $3 billion. The valuation was based on how similar layer-1 networks were priced when they first launched. The team stress-tested token price scenarios across bull and bear markets. Monad's strong funding, tech, and growing community have people talking about how high its token price could go. Coinbase's sale attracted over 85,000 buyers, who purchased tokens worth a total of $269 million.

10m
Bittensor Wallets Ranked by Security Features You Actually Need

Bittensor Wallets Ranked by Security Features You Actually Need

Multi-chain wallets treat TAO just like any other Substrate token. That's where things get tricky.

7m